课题基金 / 基金详情

Clinical and Molecular Genetical Research for the Treatment of Mitochondrial Encephalomyopathies

Clinical and Molecular Genetical Research for the Treatment of Mitochondrial Encephalomyopathies
线粒体脑肌病治疗的临床和分子遗传学研究
批准号:
09670842
负责人:
NAKANO Kazutoshi
金额:
$2.18万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 2000

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Mitochondrial encephalomyopathy is caused by mitochondrial dysfunction mainly in electron transport system in the inner mitochondrial membrane. The essential treatment has not yet been established, partly because the clinical effect of the treatment has been well evaluated from the point of the serial changes of mitochondrial enzyme activity and mitochondrial (mt) DNA analyses. We developed the methods of mitochondrial enzyme activities and mtDNA analyses in platelet (PLT). We also developed creatine monohydrate (Cr-H_2O) treatment for the mitochondrial encephalomyopathies.Miniaturized assays for isolated PLT were employed for the measurement of protein, complex II+III (II+III), complex IV (IV), and citrate synthase (CS) assays using a microplate reader. We newly developed the miniaturized assay for (IV). A3243G mutation of mtDNA was analyzed with PCR/RFLP methtod for the isolated PLT.We evaluated the stroke-like episode in a patient with MELAS and the efficacy of sodium dichloroacetat … More e (DCA) treatment using PLT mitochondrial enzyme assay. Although her muscle weakness improved with cytochrome c treatment, neurological symptoms including headache, vomiting and visual disturbance developed to intractable headache, which was a mild form of stroke-like episode. The intractable severe headache improved with DCA treatment. PLT (II+III), (IV) and (IV/CS) decreased at the stroke-like episode and DCA treatment improved PLT (II+III), (IV), and (IV/CS). Ratio of A3243G mutation of mtDNA was not changed before and after DCA treatment.Cr-H_2O was orally supplemented (0.2 g/kg/day, divided into two for the first two weeks followed by 0.08-0.12 g/kg/day twice or three times a day for 4-10 months) in two girls with MELAS due to an nt A3243G mtDNA mutation. The brain function was evaluated with frequency analysis of EEG and ^1H MRS.the results demonstrated that Cr-H_2O supplement improved the brain function of MELAS, suggesting the possibility of Cr-H_2O treatment for mitochondrial encephalomyopathy. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
K.Nakano, et al.: "Carnitine dynamics of L-carnitine intravenous and subcutaneous injection loading test with PLT carnitine assay"Bulletin (18) of Med Res Institute Tokyo Wom Med Coll. 18. 130-1 (1997)
K.Nakano等人:“利用PLT肉碱测定进行左旋肉碱静脉内和皮下注射负荷试验的肉碱动态”东京Wom Med Coll医学研究研究所公告(18)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
臼井紀久,中野和俊ら: "ミトコンドリア脳筋症患者におけるcytochrome c Vitamin B_1,B_2静注および経口投与による臨床症状の変化"日本小児臨床薬理学会雑誌. 9. 73-75 (1996)
Norihisa Usui、Kazutoshi Nakano 等:“线粒体脑肌病患者静脉注射和口服细胞色素 C 维生素 B_1、B_2 引起的临床症状的变化”日本儿科临床药理学会杂志 9. 73-75 (1996)。 )
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
臼井紀久,中野和俊 ら: "ミトコンドリア脳筋症患者におけるcytochrome c Vitamn B_1,B_2静注および経口投与による臨床症状の変化"日本小児臨床薬理学会雑誌. 9. 73-75 (1996)
Norihisa Usui、Kazutoshi Nakano 等:“线粒体脑肌病患者静脉注射和口服细胞色素 C 维生素 B_1、B_2 后临床症状的变化”日本儿科临床药理学会杂志 9. 73-75 (1996)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
35
    海外基金